Zepound

On November 8, 2023, Eli Lilly and Company’s obesity treatment Zepbound™ was approved by the U.S. Food and Drug Administration (FDA). It is projected to work better compared to other weight loss drugs on the market.

Zepbound has a unique mechanism of action that sets it apart from other weight-loss medications. It activates two hormone receptors in the body called GIP and GLP-1 receptors. GLP-1 is a hormone that helps regulate appetite and food intake. Based on preliminary lab studies, GIP is another hormone that may further reduce food cravings and calorie consumption when combined with GLP-1. It is designed to supplement diet and exercise and helps with chronic weight management.

Inactive ingredients include sodium chloride and sodium phosphate dibasic heptahydrate. Sodium hydroxide solution or hydrochloric acid solution may have been used to adjust pH. Water for injection is also added.

It is used to treat certain conditions, specifically for adults with obesity (meaning severely overweight) or who are overweight, and for those who have at least one of the following weight-related medical problems:

hypertension (high blood pressure),
type 2 diabetes (a long-term condition where your body has trouble using sugar for energy, leading to high blood sugar levels),
sleep apnea (a sleep disorder characterized by pauses in breathing during sleep), dyslipidemia (an imbalance in fats in your blood), or
cardiovascular diseases (conditions affecting the heart and blood vessels).